BPA Call HT941024A0007-HT941026FE004
- Not listed
- The Defense Health Agency awarded a $29,492.53 firm fixed-price Blanket Purchase Agreement (BPA) call to Ortho Clinical Diagnostics K.K. on March 14, 2025, for chemistry and immunoassay testing system reagents and consumable supplies. The contract, which carries an ultimate completion date of April 1, 2025, will be performed in Japan and supports U.S. military medical operations in the Indo-Pacific region. This award was not set aside for any socioeconomic category and represents a call...
- The Defense Health Agency awarded a $50,949.59 firm fixed-price BPA call to Ortho Clinical Diagnostics K.K. on September 23, 2025, for chemistry and immunoassay testing system reagents and supplies. The contract will be completed by October 24, 2025, and performance will occur in Japan. This award represents a delivery order under Ortho Clinical Diagnostics K.K.'s existing $2.875M single-award Blanket Purchase Agreement with the Defense Health Agency, which has been in effect since July 1, 2024,...
- The Defense Health Agency awarded a $17,926.76 firm fixed-price BPA call to Ortho Clinical Diagnostics K.K. on February 24, 2025, with an ultimate completion date of March 3, 2025. The contract covers Chemistry and Immunoassay Testing System (VITROS and VITROS 7600) reagents and consumable supplies to be delivered to Japan. This award was not made under a socioeconomic set-aside program and represents a delivery order against the vendor's existing blanket purchase agreement with the Defense...
- The Defense Health Agency awarded a $30,041.39 firm fixed-price contract to Ortho Clinical Diagnostics K.K., a Japanese subsidiary of the global in vitro diagnostic solutions provider, on July 25, 2025. This BPA (Blanket Purchase Agreement) call is for chemistry and immunoassay testing system reagents and supplies, with performance taking place in Japan and an ultimate completion date of September 30, 2025. The contract carries no socioeconomic set-aside designation and represents a delivery...
- The Defense Health Agency awarded a $14,025.72 firm fixed-price Blanket Purchase Agreement call to Ortho Clinical Diagnostics K.K. on September 25, 2025, for chemistry and immunoassay testing system reagents and supplies. The contract was not designated under any socioeconomic set-aside program and carries an ultimate completion date of October 10, 2025. The work will be performed in Japan, where the vendor operates as a subsidiary of the global in vitro diagnostic solutions provider Ortho...
- The Defense Health Agency awarded a $31,718.44 firm fixed-price BPA call to Ortho Clinical Diagnostics K.K., a Japanese subsidiary of the global diagnostic solutions provider Ortho Clinical Diagnostics, with a completion date of September 30, 2025. This contract supports the procurement of chemistry and immunoassay testing system reagents and supplies, which are essential consumable materials for VITROS laboratory diagnostic equipment used across U.S. military medical facilities in Japan. The...
- The Defense Health Agency awarded a $19,443.19 firm fixed-price delivery order to Ortho Clinical Diagnostics K.K. for chemistry and immunoassay testing system reagents and supplies. The contract, issued as a Blanket Purchase Agreement (BPA) call on September 4, 2025, will be completed by September 15, 2025, and supports laboratory diagnostic operations at U.S. military medical facilities in Japan. Ortho Clinical Diagnostics K.K., a Japanese subsidiary of the global in vitro diagnostic...
- On April 8, 2025, the Defense Health Agency awarded a $10,107.59 firm fixed-price delivery order to Ortho Clinical Diagnostics K.K. for chemistry and immunoassay testing system reagents and supplies. This BPA call, with an ultimate completion date of April 30, 2025, will be performed in Japan and supports laboratory diagnostic operations at U.S. military medical facilities in the Indo-Pacific region. The award carries no socioeconomic set-aside designation and is issued under an existing blanket...
- The Defense Health Agency awarded a $19,618.84 firm fixed-price call under a Blanket Purchase Agreement to Ortho Clinical Diagnostics K.K. for chemistry and immunoassay testing system reagents and supplies. The contract, which was awarded on April 25, 2025, with an ultimate completion date of May 16, 2025, will be performed in Japan. This award represents a delivery order against the vendor's larger $875,000 BPA with the Defense Health Agency that remains effective through June 2029. No...
- The Defense Health Agency awarded a $41,425.96 firm fixed-price call under a Blanket Purchase Agreement to Ortho Clinical Diagnostics K.K. for chemistry and immunoassay testing system reagents and supplies. The contract was awarded on August 5, 2025, with an ultimate completion date of September 22, 2025, and will be performed in Japan. This BPA call represents a delivery order against Ortho Clinical Diagnostics K.K.'s existing $875,000 blanket purchase agreement with the Defense Health...
- HT941024A0007Blanket Purchase Agreement
- HT941024A0007-HT941026FE004BPA Call
The Defense Health Agency awarded a Blanket Purchase Agreement (BPA) call valued at $18,146.59 to Ortho Clinical Diagnostics K.K. on November 17, 2025, for chemistry and immunoassay testing system reagents and supplies. The contract is structured as a firm fixed-price BPA call with an ultimate completion date of November 17, 2025, and will be performed in Japan. This award carries no socioeconomic set-aside designation and represents a delivery order against one of the vendor's existing indefinite-delivery vehicles with the Defense Health Agency. Ortho Clinical Diagnostics K.K., a Japanese subsidiary of the international in vitro diagnostic solutions provider Ortho Clinical Diagnostics, has been the primary supplier of VITROS chemistry and immunoassay testing system reagents and consumables to U.S. military medical facilities throughout the Indo-Pacific region since 2021. The vendor maintains four active federal contract indefinite-delivery vehicles with a combined value exceeding $7 million, including a $2.875 million BPA with the Defense Health Agency effective through June 30, 2029. The company supports critical laboratory diagnostic operations across multiple U.S. military installations in Japan, including naval hospitals in Yokosuka, Atsugi, Sasebo, and Iwakuni, as well as Yokota Air Base and Misawa Air Base, providing essential medical testing services for active duty personnel, dependents, and retirees.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $0 | 11/3/25 |